GLP-1 Receptor Agonist

GLP-1 receptor agonists (GLP-1 RAs) are drugs that bind and activate the GLP-1 receptor, a class B G protein-coupled receptor expressed in the pancreas, gastrointestinal tract, brain, heart and kidney. Shared actions include glucose-dependent augmentation of insulin secretion, suppression of glucagon, slowing of gastric emptying and reduced food intake. Approved agents are either exendin-4-based (exenatide, lixisenatide) or modified human GLP-1 analogues engineered to resist DPP-4 and extend half-life (liraglutide, dulaglutide, semaglutide). Newer unimolecular multi-agonists, such as tirzepatide, combine GLP-1 receptor activity with action at related incretin receptors.

Exenatide, first approved for type 2 diabetes in 2005, is a synthetic version of exendin-4, a peptide found in Gila monster venom. Later agents extended duration through fatty acid attachment (liraglutide, semaglutide) or fusion to an antibody fragment (dulaglutide). GLP-1 RAs are approved for type 2 diabetes and, for some agents, chronic weight management, and outcome trials have shown reductions in major cardiovascular events in people with established cardiovascular disease.

GLP-1 receptor agonists turned a short-lived gut hormone into one of the most widely used groups of peptide medicines. Native GLP-1 lasts only minutes in the blood, so the class depended on engineering: borrowing a naturally resistant peptide from the Gila monster, adding fatty acids that bind albumin, or fusing the peptide to larger proteins. The result is a family of drugs that share a mechanism but differ considerably in structure, duration and side-effect profile.

Their evidence base is large. In type 2 diabetes, they lower HbA1c with no intrinsic risk of hypoglycemia and are recommended in guidelines, particularly for people with cardiovascular disease. In the STEP 1 trial in adults with obesity, semaglutide produced a mean weight change of about -14.9% at 68 weeks versus -2.4% with placebo. Dual agonists such as tirzepatide, which also activates the GIP receptor, produced larger mean reductions in the SURMOUNT-1 trial.

The popularity of these drugs has created a market for unapproved copies. Products sold online as research chemicals or 'GLP-1 peptides' are not the approved medicines, have no verified identity, purity or sterility, and carry none of the safety monitoring behind approved products. Gastrointestinal side effects are common even with approved agents, and rarer risks are monitored through trials and post-marketing surveillance. Decisions about these medicines belong with a prescribing clinician.

“All GLP-1 receptor agonists are the same drug”

They share a receptor target but differ in structure, half-life, route and clinical results. Exenatide is based on a lizard peptide, liraglutide and semaglutide are lipidated human GLP-1 analogues, and dulaglutide is fused to an antibody fragment. Trials show differences in glucose lowering, weight effects and side effects between agents.

“GLP-1 receptor agonists work only by suppressing appetite”

Reduced appetite and food intake are part of their action, but these drugs also increase glucose-dependent insulin secretion, suppress glucagon and slow gastric emptying. Some of these effects, such as slowed gastric emptying, lessen over time with long-acting agents, while effects on glucose and body weight persist during treatment.

“Tirzepatide is just a stronger GLP-1 receptor agonist”

Tirzepatide is a single molecule that activates both the GIP and GLP-1 receptors, so it is classed as a dual incretin agonist rather than a pure GLP-1 receptor agonist. Its larger average weight reduction in trials reflects a different pharmacological design, not simply higher activity at the GLP-1 receptor.

Which GLP-1 receptor agonists are approved?

Approved members of the class include exenatide, lixisenatide, liraglutide, dulaglutide and semaglutide, with an oral form of semaglutide also available. Approvals and indications differ by country and by product. Tirzepatide is approved as a dual GIP and GLP-1 receptor agonist and is often discussed alongside the class.

What are GLP-1 receptor agonists approved to treat?

All are approved for type 2 diabetes in at least some markets, and certain agents are also approved for chronic weight management in adults with obesity or overweight with related conditions. Cardiovascular outcome trials have shown reductions in heart attack, stroke and cardiovascular death in people with established cardiovascular disease, which has led to additional labeling for some products.

What are the common side effects?

The most common side effects are gastrointestinal, including nausea, diarrhea, vomiting and constipation. In trials these were usually mild to moderate and tended to lessen over time, although they were the most frequent reason for stopping treatment. Prescribing information lists rarer risks, which is one reason these drugs are used under medical supervision.